Nemonoxacin 500 mg once daily for 7-10 days is as effective and safe as levofloxacin for treating adult CAP patients in terms of clinical cure rates, microbiological success rates, and safety profile. ClinicalTrials.gov identifier: NCT01529476.

Either 500 mg or 750 mg of oral nemonoxacin taken once daily for 7-10 days demonstrated high clinical and bacteriological success rates in Chinese adult patients with CAP. Nemonoxacin at 500 mg once daily for 7-10 days is recommended for future Phase III clinical trials. ClinicalTrials.gov identifier: NCT01537250.

No abstract

No abstract

The purpose of this study was to assess the potential of a novel pseudovirus targeting to dendritic cells (DCs) inducing T cells tolerance. To prove it, allogeneic DCs transfected of the novel pseudovirus containing Lewis X oligosaccharides with programmed death-ligand 1 were co-cultured with T cells. After mixed leukocyte reactions were performed, the proliferation, cytokines secretion, and activation marker expression of T cells were analyzed. The results demonstrated that the proliferation, cytokines secretion, and activation marker expression of T cells were suppressed after co-cultured with the pseudovirus transfected DCs. These findings suggested that DCs transfected with pseudovirus could induce T-cells tolerance, which provided a promising therapeutic means to negatively manipulate immune response in organ transplantation.